Table 1.

Clinical features and outcomes of the patients.

Case	Age (years)	Preoperative apperarence	Ca 125 (IU/mL)	Treatment	Overall Survival (months)	Outcome
1	42	Peritoneal carcinomatosis	244	Neoadjuvant chemotherapy followed by TAH, BSO, omentectomy, appendectomy BPPLND	12	DOD
2	68	Bilateral ovarian mass	750	TAH, BSO, omentectomy, appendectomy, BPPLND and adjuvant chemotherapy	33	ANED
3	40	Ovarian mass and rectosigmoid colon involvement	19	TAH, BSO, Rectosigmoid resection, BPPLND and adjuvant chemotherapy	9	AWD
4	51	Ovarian mass	20	TAH, BSO peritoneal biopsies and chemotherapy	7	ANED
5	55	Ovarian mass and rectosigmoid colon involvement	67	TAH, BSO, Subtotal colectomy, splenectomy and adjuvant chemotherapy	48	ANED
6	71	Ovarian mass peritoneal carcinomatosis	1299	Unilateral salpingo-oophorectomy, omentectomy and adjuvant chemotherapy	24	DOD
7	53	Peritoneal carcinomatosis	160	Peritoneal biopsy followed by chemotherapy	9	DOD
8	72	Ovarian mass and rectosigmoid colon involvement	13	TAH, BSO, rectosigmoid colectomy, appendectomy, cholecystectomy, BPPLND	1	DOD

Note: Massive ascites was presence in all cases. Lymph nodes were positive in 3 of 4 patients who underwent lymph node dissection. TAH: total abdominal hysterectomy. BSO: bilateral salpingooophorectomy. BPPLND: bilateral pelvic and paraaortic lymp node dissection. DOD: death of disease. ANED: Alive, no evidence of disease. AWD: Alive with disease.